Korro Bio executives to present at two major investor conferences in May 2026

Korro Bio, a biopharmaceutical company specializing in RNA editing-based genetic medicines, announced that its top executives will participate in two upcoming investor conferences in May 2026. The events include the HCW 4th Annual BioConnect Nasdaq Investor Conference on May 19 and the RBC Capital Markets Global Healthcare Conference on May 20. These presentations will highlight Korro's innovative OPERA platform, which enables precise RNA editing to develop treatments for rare and common diseases. This exposure aims to attract investor interest and provide updates on Korro's progress in advancing its genetic medicine pipeline.